Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) is a late-onset neurodegenerative disorder affecting individuals who carry a premutation expansion of the FMR1 gene. FXTAS is characterized by progressive cerebellar ataxia and intention tremor, with additional features including peripheral neuropathy, autonomic dysfunction, and cognitive decline.
- Prevalence: FXTAS affects approximately 1 in 450-500 males and 1 in 150-300 females who carry the FMR1 premutation
- Age of Onset: Typically begins in the sixth decade of life (50s-60s)
- Penetrance: Full penetrance by the eighth decade in males; females typically have milder symptoms due to X-inactivation
- Sex Distribution: More common and severe in males, reflecting the single X chromosome in males
FXTAS occurs in individuals carrying an intermediate allele (55-200 CGG repeats) known as a premutation:
- Normal: < 45 CGG repeats
- Premutation: 55-200 CGG repeats
- Full Mutation: > 200 CGG repeats (causes Fragile X syndrome)
The premutation allele leads to:
- Elevated FMR1 mRNA: The expanded CGG repeat causes aberrant methylation and increased transcription, resulting in 2-8 times normal FMR1 mRNA levels
- RNA Toxicity: The expanded mRNA forms toxic foci that sequester proteins essential for neuronal function
- Repeat-Associated Non-ATG Translation (RAN Translation): The CGG repeat can be translated in all three reading frames, producing toxic polyglycine, polyalanine, and polycysteine proteins
- FMR1 (Fragile X Mental Retardation 1): The causative gene; located on chromosome Xq27.3
- FMRP (Fragile X Mental Retardation Protein): The protein product, which is deficient in full mutation carriers but typically normal in premutation carriers
-
RNA Toxicity: Elevated FMR1 mRNA with expanded CGG repeats forms secondary structures that sequester essential RNA-binding proteins
- Pur-alpha, hnRNP A2/B1, and other proteins involved in mRNA transport and translation are sequestered into RNA foci
- This leads to dysregulation of dendritic mRNA translation critical for synaptic plasticity
-
RAN Translation: Non-ATF translation of the CGG repeat produces toxic polyglycine-containing proteins (FMRpolyG)
- FMRpolyG accumulates in neuronal nuclei
- Causes ubiquitin-positive inclusions in neurons and astrocytes
- Leads to mitochondrial dysfunction and oxidative stress
-
Mitochondrial Dysfunction:
- FMRpolyG localizes to mitochondria
- Impairs mitochondrial energy production
- Increases reactive oxygen species (ROS) production
- Contributes to neuronal vulnerability
-
Neuroinflammation:
- Activated microglia and astrocytes in affected brain regions
- Elevated cytokines including IL-1β, TNF-α, and IL-6
- Contributes to progressive neuronal loss
- Brain Atrophy: Cerebellar atrophy (especially of the cerebellar vermis) and cerebral white matter changes
- Intranuclear Inclusions: Ubiquitin-positive, FMRpolyG-containing inclusions in neurons and astrocytes throughout the brain
- Loss of Purkinje Cells: Degeneration of cerebellar Purkinje cells contributes to ataxia
- White Matter Hyperintensities: MRI shows T2/FLAIR hyperintensities in the middle cerebellar peduncles (MCP signs) and periventricular white matter
- Cerebellum: Particularly the vermis and hemispheres — accounts for ataxia
- Basal Ganglia: Contributes to tremor
- Brainstem: Involvement of red nucleus and inferior olivary nucleus
- Cerebral White Matter: Diffuse white matter disease
-
Progressive Cerebellar Ataxia
- Gait instability and truncal ataxia
- Limb incoordination
- Dysarthria (scanning speech)
- Ocular motor abnormalities (nystagmus, slowed saccades)
-
Intention Tremor
- Bilateral, asymmetric action tremor
- Typically beginning in the upper extremities
- Progressive course over years
-
Peripheral Neuropathy
- Sensory neuropathy (decreased vibration sense)
- Motor neuropathy (muscle weakness)
- Contributes to gait dysfunction
- Autonomic Dysfunction: Orthostatic hypotension, bladder dysfunction
- Cognitive Decline: Executive dysfunction, memory deficits; approximately 50% develop dementia
- Psychiatric Features: Anxiety, depression, irritability
- Parkinsonism: Resting tremor, bradykinesia in some patients
Proposed Diagnostic Criteria (Jacquemont et al., 2006):
| Feature |
Major |
Minor |
| Intention tremor |
Present |
- |
| Cerebellar ataxia |
Present |
- |
| MCP sign on MRI |
Present |
- |
| White matter hyperintensities |
- |
Present |
| Peripheral neuropathy |
- |
Present |
| Autonomic dysfunction |
- |
Present |
- Definite FXTAS: One major clinical feature + one major radiological finding
- Probable FXTAS: One major clinical feature OR one major radiological finding + at least one minor feature
- Neurological Examination: Assessment of coordination, gait, tremor, reflexes, sensation
- Cognitive Testing: MMSE, MoCA, or detailed neuropsychological evaluation
- Family History: Important for identifying premutation carriers
- FMR1 CGG Repeat Analysis: Gold standard for diagnosis
- Molecular Testing: PCR and Southern blot to determine repeat number
- MRI Brain:
- Cerebellar atrophy (vermis > hemispheres)
- T2/FLAIR hyperintensities in middle cerebellar peduncles (MCP sign)
- Periventricular and subcortical white matter hyperintensities
- Cerebral atrophy in advanced cases
- FMR1 mRNA Levels: Elevated in premutation carriers
- FMRpolyG in Blood: Potential biomarker under investigation
-
Tremor:
- Beta-blockers (propranolol): May reduce tremor
- Primidone: Sedative antiepileptic
- Benzodiazepines (clonazepam): May help tremor and anxiety
- Deep brain stimulation (VIM thalamic DBS): For severe, treatment-refractory tremor
-
Ataxia:
- Physical therapy: Gait training, balance exercises
- Occupational therapy: Adaptive strategies
- Speech therapy: For dysarthria
- No disease-modifying treatments available
-
Peripheral Neuropathy:
- Gabapentin or pregabalin for neuropathic pain
- Physical therapy
- Assistive devices (canes, walkers)
-
Cognitive/Psychiatric Symptoms:
- SSRIs for depression/anxiety
- Cholinesterase inhibitors (donepezil) if dementia develops
- Occupational therapy for functional maintenance
- Antisense Oligonucleotides (ASOs): Under investigation to reduce FMR1 mRNA levels
- Small Molecule Inhibitors: Targeting RAN translation
- Mitochondrial Protectants: CoQ10, vitamin E for oxidative stress
- Gene Therapy Approaches: Potential future direction
- Multidisciplinary Care: Neurology, genetics, psychiatry, physical/occupational therapy
- Genetic Counseling: Important for family members
- Support Groups: Fragile X Foundation resources
- Assistive Devices: As disease progresses
- Progressive Disorder: Symptoms worsen over 5-15 years
- Life Expectancy: Generally normal lifespan, but disability increases
- Cause of Death: Complications of falls, aspiration, or intercurrent infections
- Variability: Significant phenotypic variability even within families
| Condition |
CGG Repeats |
Mechanism |
| Fragile X Syndrome |
> 200 |
FMRP deficiency |
| FXTAS |
55-200 (premutation) |
RNA toxicity, RAN translation |
| FPOA |
55-200 (premutation) |
Primary ovarian insufficiency |